Source link : https://www.newshealth.biz/health-news/added-plinabulin-boosts-os-as-later-line-treatment-for-egfr-wild-type-nsclc/
Adding the investigational agent plinabulin to docetaxel in the second and third line of treatment significantly improved overall survival (OS) in patients with advanced or metastatic EGFR wild-type non-small cell cancer (NSCLC), the phase III DUBLIN-3 trial showed. Among 559 patients, the median OS was 10.5 months with plinabulin plus docetaxel compared with 9.4 months […]
Author : News Health
Publish date : 2024-09-10 21:00:10
Copyright for syndicated content belongs to the linked Source.